Table 18.1 Recent literature reports on the usage of FbD for design and development of various

kinds of lipidic drug nanoconstructs

Lipid-based nanoconstructs

Carrier

Drug

Design

IF

RV

References

Vesicular carrier systems

Liposomes

Lamivudine

FFD

2

3

Godbole et al. (2020)

Erlotinib

BBD

3

2

Dhoble and Patravale

(2019)

Pravastatin

D-OD

4

7

Sylvester et al. (2018)

Niosomes

Polymyxin B

BBD

3

4

Chauhan and Bhatt (2019)

Methotrexate

BBD

3

2

Abdelbary and

AbouGhaly (2015)

Sumatriptan

succinate

TgD

4

3

González-Rodríguez et al.

(2012)

Ethosomes

Fisetin

BBD

3

3

Moolakkadath et al.

(2018)

Tramadol

BBD

3

3

Ahmed et al. (2016)

Diclofenac

FD

2

4

Jain et al. (2015b)

Transferosomes

Zolmitriptan

BBD

3

3

Pitta et al. (2018)

Risperidone

CCD

2

2

Das et al. (2017)

Sildenafil

PBD

5

2

Ahmed (2015)

Bilosomes

Tizanidine HCl

FFD

3

3

Khalil et al. (2018)

Tenoxicam

FFD

3

4

Al-mahallawi et al. (2015)

Elastomers

Diacerein

FD

2

5

Aziz et al. (2018)

Non-vesicular systems

Solid lipid

nanoparticles

Quetiapine

fumarate

CCD

2

1

Agarwal et al. (2020)

Carvedilol

BBD

3

5

El-Say and Hosny (2018)

Rosuvastatin

CCD

2

3

Beg et al. (2017a)

Nanostructured lipidic

carriers

Ibrutinib

CCD

3

3

Rangaraj et al. (2020)

Isradipine

BBD

3

3

Alam et al. (2018)

Telmisartan

BBD

3

3

Thapa et al. (2018)

Emulsifying systems

Supersaturable

SNEDDS

Sorafenib

tosylate

D-OD

3

4

Sharma et al. (2020)

Celecoxib

D-OD

4

3

Chavan et al. (2015)

Trans-

resveratrol

CCD

2

2

Singh and Pai (2015)

Liquid SNEDDS

Darunavir

IV-OD

3

5

Garg et al. (2018)

Valsartan

CCD

4

3

Bandyopadhyay et al.

(2015)

Carvedilol

CCD

3

4

Singh et al. (2011b)

Cationic SNEDDS

Raloxifene

D-OD

3

4

Jain et al. (2018)

Olmesartan

MD

3

3

Beg et al. (2015b)

Candesartan

cilexetil

MD

3

2

Sharma et al. (2015)

(continued)

330

B. Singh et al.